Seibel Nita L
Clinical Investigations Branch, Cancer Treatment Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Hematology Am Soc Hematol Educ Program. 2008:374-80. doi: 10.1182/asheducation-2008.1.374.
Survival of children with acute lymphoblastic leukemia (ALL) is often described as the success story for oncology. The improvements in the treatment of ALL represent the work of cooperative groups at their best. Fifty years ago a pediatric oncologist would have never considered using the term "cure" in a discussion with a family whose child was diagnosed with ALL. Today the term is not only used in the initial discussion but referred to frequently thereafter. However, as we all know, cure is not assured and is not obtained without sequelae. This review will focus on the improvements in treatment for newly diagnosed ALL in children and adolescents according to risk group and some of the challenges that remain despite the improved outcome.
急性淋巴细胞白血病（ALL）患儿的生存情况常被视为肿瘤学领域的成功范例。ALL治疗方面的进步充分展现了协作组的卓越工作。五十年前，儿科肿瘤学家在与被诊断为ALL的患儿家庭讨论时，绝不会考虑使用“治愈”这个词。如今，这个词不仅在初次讨论中会被提及，之后还会被频繁提及。然而，众所周知，治愈并非有保证的，而且治愈后也会有后遗症。本综述将聚焦于根据风险分组对新诊断的儿童和青少年ALL治疗的改进，以及尽管治疗效果有所改善但仍然存在的一些挑战。
